Kieferpix / iStockphoto.com
The US Patent and Trademark Office (USPTO) has granted ERS Genomics its first US patent covering the use of CRISPR/Cas9 technology for gene editing.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Emmanuelle Charpentier, USPTO, CRISPR-Cas9 patent, genomics research, gene technology